Shelter Pharma (543963) Q4 19/20 earnings summary

Executive summary

• FY20 revenue increased to Rs 30,06,52,468 from Rs 27,73,12,401; profit after tax was Rs 7,08,288, up from Rs 6,01,522.

• Manufacturing covers pharmaceutical products and animal feed supplements; factory repairs and expansion are intended to increase future manufacturing capacity.

Financial highlights

• Revenue from operations: Rs 30,06,52,468 in FY20 vs Rs 27,73,12,401 in FY19; other income was Rs 47,023 vs Rs 2,03,938.

• Profit before tax: Rs 9,38,628 vs Rs 8,02,994; profit after tax: Rs 7,08,288 vs Rs 6,01,522.

• Profit before depreciation and tax: Rs 19,83,762 vs Rs 22,55,333; depreciation was Rs 13,16,705 vs Rs 11,80,768.

• Total expenses were Rs 29,97,60,863 vs Rs 27,67,13,345; cost of raw materials consumed was Rs 27,10,95,609 vs Rs 25,87,60,291.

Outlook and guidance

• Factory-premises repairs and expansion are expected to enhance manufacturing capacity in coming years; operations remained focused on pharma products and animal feed supplements.